Leaderboards/Peptidase Inhibition and Analysis

Peptidase Inhibition and Analysis

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Shahin Ramazi
Tarbiat Modares University
2
Oliver Hsia
University of Dundee
3
Xi‐Yang Cui
Chinese Academy of Medical Sciences & Peking Union Medical College
4
Johannes Popow
Boehringer Ingelheim (Austria)
5
Zhibo Ma
Chinese Academy of Medical Sciences & Peking Union Medical College
6
Youmei Xiao
Sun Yat-sen University
7
Joris L. Vos
Memorial Sloan Kettering Cancer Center
8
Peng Tan
China Agricultural University
9
Miljan Kuljanin
Harvard University
10
Jacopo Millul
University Hospital of Basel

Papers

1
Publication in Nature (2024) [181 citations, W4391994105]
Nature|2024
181 cit.
2
Covalent targeted radioligands potentiate radionuclide therapy
Nature|2024
165 cit.
3
Publication in Science (2024) [158 citations, W4402625837]
Science|2024
158 cit.
4
A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy
Nature Communications|2025
72 cit.
5
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
JCI Insight|2024
16 cit.
6
Enhanced contrast in FAP-targeting PET imaging with 61Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [61Cu]Cu-Kalios PET radioligands
EJNMMI Radiopharmacy and Chemistry|2025
3 cit.
7
Publication in Journal of the American Chemical Society (2026) [2 citations, W7125434031]
Journal of the American Chemical Society|2026
2 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Haojun Chen
Wuhan University
2
Daniel A. Bachovchin
Memorial Sloan Kettering Cancer Center
3
Youqiong Ye
Shanghai Jiao Tong University
4
Leigh Ann Kerns
Cleveland Clinic
5
Macarena Lagos Gomez
Clínica Alemana
6
Fanny Fouyssac
Unknown
7
Aziz Bousfiha
University of Hassan II Casablanca
8
Kanyi Pu
Nanyang Technological University
9
Xiaoyu Yang
Shanghai University of Traditional Chinese Medicine
10
Eric S. Fischer
Dana-Farber Cancer Institute

Papers

1
The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity
Journal of Clinical Immunology|2022
492 cit.
2
Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics
Nature Biomedical Engineering|2022
252 cit.
3
Molecular radio afterglow probes for cancer radiodynamic theranostics
Nature Materials|2023
190 cit.
4
Renal clearable polyfluorophore nanosensors for early diagnosis of cancer and allograft rejection
Nature Materials|2022
189 cit.
5
A Dual‐Locked Activatable Phototheranostic Probe for Biomarker‐Regulated Photodynamic and Photothermal Cancer Therapy
Angewandte Chemie International Edition|2022
169 cit.
6
Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine
Nature Biomedical Engineering|2023
157 cit.
7
Reconstruction of the tumor spatial microenvironment along the malignant-boundary-nonmalignant axis
Nature Communications|2023
149 cit.
8
Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy
Nature Communications|2022
139 cit.
9
Activatable Cancer Sono‐Immunotherapy using Semiconducting Polymer Nanobodies
Advanced Materials|2022
132 cit.
10
Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy
Advanced Materials|2022
116 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
William McGuire
University of York
2
Morten Meldal
University of Copenhagen
3
Eric N. Olson
Southwestern Medical Center
4
Kenneth C. Anderson
Dana-Farber Cancer Institute
5
Benjamin F. Cravatt
Scripps Institution of Oceanography
6
Frank Wuest
University of Alberta
7
Jesús F. San Miguel
Clinica Universidad de Navarra
8
Alfred L. Goldberg
Harvard University
9
Erkki Ruoslahti
Sanford Burnham Prebys Medical Discovery Institute
10
Motoharu Seiki
Kanazawa University

Papers

1
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science|1987
11.7k cit.
2
Peptidotriazoles on Solid Phase:  [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides
The Journal of Organic Chemistry|2002
8.5k cit.
3
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Nature Communications|2017
7.6k cit.
4
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology|2014
4.9k cit.
5
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule
Nature|1984
3.7k cit.
6
Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy
Cell|2004
3k cit.
7
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
New England Journal of Medicine|2003
2.6k cit.
8
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Cell|1998
2.6k cit.
9
A matrix metalloproteinase expressed on the surface of invasive tumour cells
Nature|1994
2.6k cit.
10
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
Cell|1994
2.5k cit.

Reagents for Peptidase Inhibition and Analysis

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

ProteintechEvidence 75

PD-L1/CD274

Cited in 9 papers
#PY5P5-FcA98166-4$267
View Evidence →
ProteintechEvidence 75

FcZero-rAb® PE Anti-Human PD-L1/CD274 Rabbit Recombinant Antibody

Cited in 9 papers
#PE-FcA98062$190
View Evidence →
ProteintechEvidence 75

PD-L1/CD274

Cited in 9 papers
#PE-FcA98166-4$140
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 68

TPX2 Antibody

Cited in 19 papers
#8559$136,317
View Evidence →
Cell Signaling TechnologyEvidence 65

CDK8 (D6M3J) Rabbit Monoclonal Antibody

Cited in 13 papers
#17395$161,351
View Evidence →
Cell Signaling TechnologyEvidence 61

PathScan® Phospho-PDGF Receptor alpha/beta (panTyr) Sandwich ELISA Kit

Cited in 10 papers
#7235$66,129,740
View Evidence →